From cell-replacement clinical trials to the CGMs worn by millions, these are the companies and research bodies doing the work. Programs linked to our Cure Tracker where applicable.
Companies developing drugs, cell therapies, and gene therapies targeting a functional cure or disease modification.
Leading T1D cell-replacement therapy developer. Programs VX-880 (zimislecel, stem cell-derived islets with immunosuppression) and VX-264 (encapsulated islets, immunosuppression-free) are among the most advanced cure-track programs in the world.
Programs in our Cure Tracker
Engineering hypoimmune (immune-evasive) cells designed to avoid rejection without chronic immunosuppression. UP421 and SC451 are their T1D programs. Early human data has been reported.
Programs in our Cure Tracker
Developing the Cell Pouch — an implantable device that grows its own blood supply for donor islet cells. Partners with Vertex on next-generation immune-protection strategies.
Programs in our Cure Tracker
Manufacturer of Tzield (teplizumab), the first FDA-approved therapy to delay onset of T1D in at-risk individuals. Originally developed by Provention Bio.
Programs in our Cure Tracker
Using CRISPR gene editing to engineer insulin-producing cells that can evade the immune system without immunosuppression. Early research stage for T1D.
Programs in our Cure Tracker
Companies building continuous glucose monitors (CGM), insulin pumps, and automated insulin delivery (AID) systems.
Maker of FreeStyle Libre — the world's most widely used flash CGM system. Libre 3 is a real-time CGM with 14-day wear. Abbott's technology is integral to international AID system development.
Maker of the t:slim X2 insulin pump with Control-IQ technology — an advanced hybrid closed-loop AID system. Tandem's software-upgradeable platform is a leading choice among T1D tech users.
Foundations and charities that fund T1D research programs, including many of the cure-track trials in our tracker.
Formerly JDRF, rebranded 2023. The world's largest non-governmental funder of T1D research. Has funded or co-funded most of the cure programs in our tracker. Also drives global regulatory policy and trial access.
Government agencies funding foundational science and running major natural-history and prevention studies.
The National Institute of Diabetes and Digestive and Kidney Diseases funds foundational T1D research, TrialNet (the largest T1D natural history and prevention network), and the TEDDY study.